Early detection of hemangiosarcoma and angiosarcoma
View Patent ↗A variety of methods, compositions and kits are provided for the early detection, diagnosis and treatment of hemangiosarcoma in dogs and angiosarcomas in humans.
1. A method for early detection of hemangiosarcoma in a dog, the method comprising:
(a) providing a population of cells obtained from a blood sample from the dog;
(b) determining (i) the level at which cells within the cell population concurrently express a plurality of cell markers, the plurality of cell markers comprising at least one primitive hematopoietic cell marker and at least one endothelial cell marker, and (ii) whether or not cells within the cell population express at least one leukemia cell marker or leukocyte-specific cell marker, wherein
the at least one primitive hematopoietic cell marker is selected from the group consisting of CD117, CD34, and CD133;
the at least one endothelial cell marker is selected from the group consisting of CD51/CD61, CD31, CD105, CD106 CD146 and von Willebrand Factor (vWF); and
the at least one leukemia cell marker or leukocyte-specific cell marker is selected from the group consisting of CD18, CD3, CD5, CD21 and CD11b; and
(c) comparing the level at which cells in the cell population concurrently express the plurality of cell markers with a control level of concurrent expression of the markers, wherein (1) an increase in the expression level of the plurality of cell markers relative to the control expression level, and (2) the absence of expression of CD18, CD3, CD5, CD21 and/or CD11b collectively are an indication of hemangiosarcoma.
2. The method of claim 1 , wherein the determining comprises
incubating the population of cells with labeled antibodies that specifically bind the at least one primitive hematopoietic cell marker, the at least one endothelial cell marker and the at least one leukemia cell marker or leukocyte-specific cell marker under conditions such that cells expressing the markers become labeled, and wherein antibodies that bind different markers are differentially labeled; and
detecting labeled cells by multiparameter flow cytometry.
3. The method of claim 2 , wherein the dog is a purebred dog from a breed where the prevalence of hemangiosarcoma is high, or a mix breed dog containing predominant derivation from a breed where the prevalence of hemangiosarcoma is high.
4. The method of claim 2 , wherein one or more of the antibodies is labeled using a secondary detection scheme to increase sensitivity of the method.
5. The method of claim 3 , wherein the breed is selected from the group consisting of a Golden Retriever, a German Shepherd, a Portuguese Water Dog, or a Skye Terrier.
6. The method of claim 1 , wherein the determining comprises determining the level at which cells in the population of cells concurrently express at least one primitive hematopoietic cell marker selected from the group consisting of CD117, CD133 and CD34.
7. The method of claim 1 , wherein the determining comprises determining the level at which cells in the population of cells concurrently express at least one leukemia cell marker or leukocyte-specific cell marker selected from the group consisting of CD18, CD3, CD5, CD21 and CD11b.
8. The method of claim 1 , wherein the determining comprises determining the level at which cells in the population of cells concurrently express CD117, CD34, CD51/CD61, and CD18, and/or CD3, CD5, CD21 or CD11b.
9. The method of claim 1 , wherein the determining step further comprises determining the fraction of cells in the cell population that concurrently express the plurality of cell markers;
the control is a threshold level representative of the fraction of cells that currently express the plurality of cell markers in a control population; and
the comparing step comprises comparing the fraction of cells in the cell population that concurrently express the plurality of cell markers with the threshold level.
10. The method of claim 9 , wherein the determining step further comprises (i) incubating the population of cells with differentially labeled antibodies that specifically bind to CD117, CD34, CD51/61, and CD18 and/or CD3, CD5, CD21 or CD11b under conditions such that cells expressing CD117, CD34, CD51/61, and CD18 and/or CD3, CD5, CD21 or CD11b become labeled; and (ii) detecting labeled cells by multiparameter flow cytometry.
11. The method of claim 1 , wherein the expression level of the plurality of cell markers is determined at the mRNA level.
12. The method of claim 1 , wherein the expression level of the plurality of cell markers is determined at the protein level.
13. A method for assessing risk of hemangiosarcoma, the method comprising:
(a) obtaining a population of cells from a blood sample of a dog; and
(b) determining the level at which cells within the cell population express at least one primitive hematopoietic cell marker, at least one endothelial cell marker and at least one leukemia cell marker or leukocyte-specific cell marker, wherein
the at least one primitive hematopoietic cell marker is selected from the group consisting of CD117, CD34 and CD133;
the at least one endothelial cell marker is selected from the group consisting of CD51/CD61, CD31, CD105, CD106, CD146 and von Willebrand Factor (vWF);
the at least one leukemia cell marker or leukocyte-specific cell marker is selected from the group consisting of CD18, CD3, CD5, CD21 and CD11b; and
(c) comparing the level at which cells in the cell population concurrently express the at least one primitive hematopoietic cell marker and at least one endothelial cell marker with a control level of concurrent expression of the markers and comparing the level at which the cells express the at least one leukemia or leukocyte-specific marker with a control level of the leukemia or leukocyte-specific marker and thereby assessing the risk of hemangiosarcoma.
14. The method of claim 13 , wherein the determining step comprises
incubating the population of cells with labeled antibodies that specifically bind the at least one primitive hematopoietic cell marker, the at least one endothelial cell marker and the at least one leukemia cell marker or leukocyte-specific cell marker under conditions such that cells expressing the markers become labeled, and wherein antibodies that bind different markers are differentially labeled; and
detecting labeled cells by multiparameter flow cytometry.